Navigation Links
Data published in the New England Journal of Medicine support use of raxibacumab (ABthrax) for the treatment of inhalation anthrax
Date:7/9/2009

ROCKVILLE, Maryland July 9, 2009 Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced publication by the New England Journal of Medicine of the results of two pivotal animal efficacy studies, which showed the life-saving potential of the Company's human monoclonal antibody drug raxibacumab (ABthrax), as well as the results of human safety studies, which supported the use of raxibacumab in the event of life-threatening inhalation anthrax disease.

"The results published today showed that a single dose of raxibacumab was highly effective as a treatment for inhalation anthrax in both rabbits and monkeys," said Sally D. Bolmer, Ph.D., R.A.C, lead author and Senior Vice President, Development and Regulatory Affairs, HGS. "Raxibacumab acted quickly to provide a significant survival benefit to animals showing clinical signs of disease caused by exposure to a dose of aerosolized anthrax spores that was approximately 200 times the median lethal dose. We also note that the safety profile shown in healthy human volunteers provides support for use of raxibacumab in the clinical setting of immediately life-threatening inhalation anthrax disease."

Raxibacumab represents a new way to address the anthrax threat. While antibiotics can kill the anthrax bacteria, they are not effective against the deadly toxins that the bacteria produce. Raxibacumab targets anthrax toxins after they are released by the bacteria into the blood and tissues. In an inhalation anthrax attack, people may not know they are infected with anthrax until the toxins already are circulating in their blood, and it may be too late for antibiotics alone to be effective.

"We are very proud that the importance of these data and the rigor and high quality of our scientists' work have led to publication in The New England Journal of Medicine," said David C. Stump, M.D., Executive Vice President, Research and Development, HGS. "Based on these results, we believe raxibacumab has the potential to be a significant step forward in the treatment of inhalation anthrax."


'/>"/>

Contact: Jerry Parrott
301-315-2777
Edelman Public Relations
Source:Eurekalert

Related biology news :

1. First comprehensive guidelines for managing medullary thyroid carcinoma published in Thyroid journal
2. Ambati study published in PNAS
3. Major aspergillus genomics supplement published by journal Fungal Genetics and Biology
4. Nutrigenomics -- developing personalized diets for disease prevention -- part 2 just published in OMICS
5. Special issue Comparative Cognition in Context now published
6. Results of the third school nutrition dietary assessment study published
7. High school students paper published in prestigious college math journal
8. Journal of Nutrition, Health and Aging to be published by Springer
9. PTC124 shows activity in cystic fibrosis; Phase 2 proof-of-concept data published in Lancet
10. Issue 1 of Energy and Environmental Science published on Web
11. Duck-billed platypus genome sequence published
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):
(Date:5/26/2016)... READING, England , May 26, 2016 ... a leading global provider of clinical, commercial and ... organisations and TranScrip ( http://www.transcrip-partners.com ), a renowned ... product lifecycle, today announced the extension of their ...      (Logo: http://photos.prnewswire.com/prnh/20141208/720248 ) , ...
(Date:5/26/2016)... , May 26, 2016 Despite the ... value in this space. Today,s pre-market research on ActiveWallSt.com directs ... Health Inc. (NASDAQ: RDUS ), Cerus Corp. (NASDAQ: ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... briefings at: http://www.activewallst.com/ On ...
(Date:5/26/2016)... San Diego, CA (PRWEB) , ... May 26, ... ... assay development and manufacturing company, today announced several positive developments that position the ... As a result of the transaction, Craig F. Kinghorn has been appointed ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lajollacooks4u has become a rising hotspot for specialized ... of its top attractions. Fortune 500 companies, such as Illumina, Hewlett-Packard, Qualcomm and ... intimate team-building experience. , Each event kicks off with an olive oil and salt-tasting ...
Breaking Biology Technology: